Key result
Ranolazine reduces CRP levels ~23% in stable CAD while trimetazidine shows no effect.
Why the study?
Ranolazine and trimetazidine both reduce inflammatory parameters in CAD, but no direct comparison between them had been made.
Does ranolazine compared to trimetazidine improve markers of inflammation in patients with stable coronary artery disease?
RCT (n=56)
Double-blind
Computer software (Research Randomizer)
No
Does ranolazine compared to trimetazidine improve markers of inflammation in patients with stable coronary artery disease?
Ranolazine demonstrates an effect on reducing inflammatory markers in patients with stable CAD, whereas trimetazidine does not.
Answers are grounded in this paper and cite their sources.
May lower CRP with ranolazine but not trimetazidine in stable CAD; hypothesis-generating and should not yet change practice.
Purpose: Ranolazine and trimetazidine have been individually shown to reduce the levels of inflammatory parameters in patients with coronary artery disease (CAD). However, no direct comparison between these two drugs has been made in these patients. The aim was to compare the effects in patients with stable CAD of ranolazine and trimetazidine on C-reactive protein (CRP), tumor necrosis factor- (TNF-), interleukin (IL)-6 and IL-10, and vascular adhesion molecule (VCAM) 1.
No takes yet. Share an insight, caveat, or question.
Miran Šebeštjen (2021) conducted an RCT in Stable Coronary Artery Disease (n=56). Ranolazine vs. Trimetazidine 35 mg twice daily was evaluated on C-reactive protein (CRP) levels at 12 weeks (p=0.045). Ranolazine significantly decreased C-reactive protein levels by 23.2% in patients with stable coronary artery disease, whereas trimetazidine had no significant effect.
Synapse has enriched 10 related papers. Consider them for comparative context: